Retatrutide: Triple Agonist Research Overview
For laboratory research use only. Not for human use. Research use only.
Retatrutide is a novel triple receptor agonist that simultaneously targets GIP (glucose-dependent insulinotropic polypeptide), GLP-1 (glucagon-like peptide-1), and glucagon receptors. It has emerged as one of the most studied compounds in metabolic disease research, with Phase 3 clinical trials demonstrating significant weight reduction outcomes. This overview covers the current research landscape for Australian researchers.
What is Retatrutide?
Retatrutide (LY3437943) is a once-weekly injectable peptide developed by Eli Lilly. It is a triagonist — meaning it activates three distinct receptor pathways simultaneously: GIP, GLP-1, and glucagon receptors. This triple mechanism distinguishes it from earlier GLP-1 agonists such as Semaglutide and dual agonists such as Tirzepatide.
In Phase 2 clinical trials published in The New England Journal of Medicine (2023), participants receiving the highest dose of Retatrutide achieved a mean body weight reduction of 24.2% over 48 weeks — the largest reduction observed in any pharmacological weight loss trial at that time.
Triple Agonist Mechanism
The GIP receptor component of Retatrutide is thought to enhance insulin secretion and improve insulin sensitivity. The GLP-1 receptor component reduces appetite and slows gastric emptying. The glucagon receptor component increases energy expenditure and promotes fat oxidation — a mechanism not present in GLP-1 or dual GIP/GLP-1 agonists.
This triple mechanism is hypothesised to produce additive or synergistic effects on weight reduction and metabolic parameters compared to single or dual agonists. Phase 3 trials are ongoing to characterise the full efficacy and safety profile.
Phase 3 Trial Status
As of 2026, Retatrutide is in Phase 3 clinical development across multiple indications including obesity, type 2 diabetes, and non-alcoholic steatohepatitis (NASH). The TRIUMPH programme encompasses several large-scale trials with results expected in 2026-2027.
Phase 2 data demonstrated dose-dependent weight reduction with the 12mg weekly dose producing the most significant outcomes. Researchers and clinicians globally are monitoring Phase 3 results closely given the unprecedented Phase 2 efficacy data.
Research Availability in Australia
Retatrutide is not currently approved by the TGA as a therapeutic agent in Australia. PeptideIQ supplies research-grade Retatrutide for laboratory research use only, manufactured to ≥98% purity with third-party HPLC verification and full Certificate of Analysis.
Australian researchers studying GLP-1/GIP/glucagon receptor pathways, metabolic disease models, or comparative peptide pharmacology can source research-grade Retatrutide through PeptideIQ with express delivery Australia-wide.
Frequently Asked Questions
How does Retatrutide differ from Semaglutide?
Semaglutide is a single GLP-1 receptor agonist. Retatrutide is a triple agonist targeting GIP, GLP-1, and glucagon receptors simultaneously. Phase 2 data suggests Retatrutide produces greater weight reduction than Semaglutide, though direct head-to-head trials are ongoing.
Is Retatrutide available in Australia?
Retatrutide is not TGA-approved for human use in Australia. PeptideIQ supplies research-grade Retatrutide for laboratory research use only.
What is the purity of PeptideIQ's Retatrutide?
PeptideIQ supplies Retatrutide at ≥98% purity verified by third-party HPLC testing, with a full Certificate of Analysis for each batch.
Disclaimer: All products supplied by PeptideIQ are for laboratory research use only. They are not approved for human use, consumption, or therapeutic application. PeptideIQ complies with all applicable Australian regulations including the Therapeutic Goods Act 1989.